Pharmiweb.com RSS Feeds 
PharmiWeb Candidate Blog
Press Release
Alizyme Acquires Patent And Intellectual Property
AlizymePosted on:18 Mar 05COLAL® is a drug delivery technology which enables drugs to be taken orally and then be specifically released when the preparation reaches the colon. The technology is currently being exploited in the development of COLAL-PRED®, Alizyme’s novel product for the treatment of ulcerative colitis, which recently received approval for a pivotal Phase III clinical trial in
The patents are currently granted in the major commercial territories, including the
In respect of those patents that relate to the COLAL® drug delivery technology that cover Alizyme’s COLAL-PRED® product, the terms of the deal provide that Alizyme pays £750,000 on signature of the agreement and a further £550,000 on recording the assignments at the appropriate patent offices. Alizyme will take outright ownership of these patents, with no further amounts being payable.
In respect of the other assigned patent families, which relate to other aspects of colonic drug delivery technology, Alizyme will pay a total of £75,000 over the next three years, royalties on any sales of relevant products and a share of any other consideration received by Alizyme for exploitation of these patents. Alizyme will look to identify new potential product opportunities in conjunction with this drug delivery technology.
Commenting, Dr Richard Palmer, Chief Executive Officer said:
“We are pleased to have acquired this intellectual property estate. This transaction is in line with our policy of owning, where possible, the intellectual property supporting our existing products, to give us flexibility in developing new products and in leveraging the maximum commercial value from our portfolio.”
For further information, please contact:
|
Dr Richard Palmer, Chief Executive Officer |
|
|
Tim McCarthy, Finance Director |
|
|
ALIZYME plc |
+44 (0) 1223 896000 |
|
|
|
|
Lisa Baderoon/Rebecca Skye Dietrich |
|
|
BUCHANAN COMMUNICATIONS |
+44 (0) 20 7466 5000 |
Further information on Alizyme can be found on the Company’s website: www.alizyme.com
Editor’s Note
Alizyme plc
Alizyme is a speciality pharmaceutical development company, based in
COLAL®
COLAL® is a drug delivery technology which enables drugs to be taken orally and then be specifically released when the preparation reaches the colon. Achieving colonic release with conventional oral dosage forms has proved difficult because of the variation between individuals in transit times and conditions within the gastrointestinal tract. COLAL® overcomes this difficulty by covering small pellets containing the drug with a coating of ethylcellulose and a specific form of amylose (derived from starch). This coating prevents drug release in the stomach and small intestine. When the pellets reach the colon the amylose in the coating is broken down by bacterial enzymes and the drug is released.
(Note: COLAL® and COLAL-PRED® are registered trademarks of Alizyme Therapeutics Limited)
The identification of compounds for successful research, their progress through development and the obtaining of regulatory approvals or authorisations before marketing, manufacture and/or distribution of products is not certain or a formality.
For more information:
http://www.alizyme.com
Dr Richard Palmer, Chief Executive
ALIZYME plc
http://www.alizyme.com
+44 (0) 20 7466 5000
anne@alizyme.co.uk
Last updated on: 27/08/2010 11:40:18
